Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 109 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Dashboard

Post-HSCT Patient monitoring surface
Generated 2026-07-02 18:37 · Post-HSCT Patient · Data Jan 08, 2026 to Jul 02, 2026 · Day 109 post-treatment
Ruxolitinib (Jakavi) response - single-patient causal analysis
+156.7%
vs pre-treatment baseline - p<0.001 - large effect (d=1.76)
HRV (RMSSD)+156.7%strong p<0.001Lowest HR-17.6%strong p<0.001Average HR-15.3%strong p<0.001Sleep Efficiency+4.2%strong p<0.001

Wearable-derived autonomic signals improved after ruxolitinib start; exploratory single-patient research analysis.

Days post-HSCT952
Days on ruxolitinib109
Data throughJul 02, 2026
Current HRV25.5ms-6.1% vs prior week
Data startJan 08, 2026RuxolitinibMar 16, 2026HEV diagnosisMar 18, 2026Data throughJul 02, 2026
HRV treatment effectActual vs counterfactual when available
Weekly snapshot
as of Jul 02, 2026
HRV
25.5ms
▼-6.1%vs prior week
Lowest HR
58bpm
▸-0.5%vs prior week
Avg HR
67bpm
▸+0.1%vs prior week
Sleep duration
7.4h
▲+8.1%vs prior week
Readiness
81
▲+5.0%vs prior week
SpO2
94.8%
DOCTOR SUMMARY

Doctor summary

  • Temp Deviation improved -50.6% to 0.12 °C
  • Steps improved +32.7% to 3692 steps
  • HRV (RMSSD) declined -6.1% to 25.5 ms -- monitor
  • Day 109 on ruxolitinib (started 2026-03-16)
Open weekly tracker
New here?AboutFull AnalysisWeekly Tracker
REPORT DIRECTORY

Report directory

Core4 reports
Full AnalysisHeart rate, HRV, sleep, activity, SpO2, and readiness trends across the full observation window.CoreBiomarker TrendsComposite biomarker indices combining multiple Oura signals into research-use summary scores.CoreSleep AnalysisSleep architecture, staging distribution, efficiency, and circadian rhythm analysis.CoreWeekly TrackerOne-page weekly tracker with watchpoints, week-over-week deltas, and clinician-style summary text.Core
Clinical6 reports
Causal: RuxolitinibBayesian causal impact and interrupted time-series analysis of ruxolitinib response.ClinicalGvHD PredictionHidden Markov and state-space models predicting GvHD flare probability from wearable signals.ClinicalSpO2 & BOSSpO2 trend monitoring and bronchiolitis obliterans syndrome screening thresholds.ClinicalRux ForecastNear-term HRV and heart-rate recovery forecast from the current post-treatment trajectory.ClinicalResearch SynthesisTwo-hit autonomic recovery hypothesis with live KPIs, timeline, and statistical evidence.ClinicalTreatment ReportPrimary clinical report covering all systems and both medicines for specialist review.Clinical
Advanced5 reports
Advanced HRVFrequency-domain HRV, Poincare plots, DFA, sample entropy, and autonomic balance metrics.AdvancedDigital TwinUnscented Kalman Filter digital twin tracking latent inflammatory and autonomic states.AdvancedFoundation ModelChronos foundation model forecasting with prediction intervals and anomaly scoring.AdvancedAnomaly DetectionMatrix Profile, Isolation Forest, and CUSUM anomaly detection across biometric channels.Advanced3D DashboardInteractive 3D scatter of sleep, HRV, and activity with treatment phase coloring.Advanced
Comparative8 reports
Autonomic ComparisonHRV and resting HR recovery trajectories compared between post-HSCT and post-stroke patients.ComparativeTreatment ResponseChangepoint detection and pre/post treatment response with Mann-Whitney U tests.ComparativeSleep ArchitectureSleep architecture, efficiency, and timing compared against clinical benchmarks.ComparativeActivity-RecoveryActivity-recovery coupling analysis: does day N activity predict day N+1 recovery?ComparativeAnomaly PatternsAnomaly fingerprinting and clustering: how bad days manifest differently.ComparativeBreathing AnalysisRespiratory-rate trends, week-over-week shifts, and outlier nights against recent baseline.ComparativeTemperature AnalysisTemperature deviation tracking, excursion alerts, and post-treatment change patterns.ComparativeP2 ChangepointsPatient 2 changepoint scan of HRV, sleep, and recovery markers around key timeline events.Comparative
Statistical4 reports
Piecewise ITSPiecewise ITS regression with AR(1) errors: two-intervention model with date sensitivity analysis.StatisticalSequential CISequential Bayesian CausalImpact isolating Jakavi and beta-blocker effects in separate runs.StatisticalPlacebo TestsFalsification tests at 20 random pre-treatment dates to calibrate false positive rates.StatisticalTau-U EffectsTau-U and NAP effect sizes for single-case experimental design with baseline trend correction.Statistical
Individual2 reports
P2 DashboardPost-stroke patient P2: HRV, HR, sleep, and activity dashboard.IndividualP3 DashboardHealthy control P3: baseline HRV, HR, sleep, and activity reference.Individual
Context2 reports
AboutMethodology, limitations, and honest assessment of what this system can and cannot do.ContextNext StepsPlanned analyses, validation targets, and next steps for the digital twin platform.Context
Data window: January 08 to July 02, 2026 · Post-treatment: day 109 on ruxolitinib · Generated: 2026-07-02 18:37
Oura Ring Gen 4 consumer wearable data; N=1 exploratory case study; not a medical device. MIT License · © 2026 The Educational Equality Institute · Oura® is a registered trademark of Oura Health Oy.